Nevanac

Alcon has launched Nevanac (nepafenac) for the prevention and treatment of post-operative pain and inflammation associated with cataract surgery.

Nevanac (nepafenac) is a topical NSAID for use in preventing and managing post-operative pain. Nepafenac is a prodrug, it penetrates the cornea and is converted to its active metabolite amfenac. Amfenac then inhibits the action of cyclooxygenase thereby inhibiting prostaglandin production.

Treatment should be started on the day before cataract surgery and continued for up to three weeks after surgery. Drops should be applied to the affected eye(s) three times daily with an additional drop 30-120 minutes prior to surgery.

As with other NSAIDs, nepafenac is contraindicated in patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDS.

View Nevanac drug record

Further information: Alcon

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases